Proteon Therapeutics

Proteon Therapeutics is a biopharmaceutical company that specializes in the development of novel, first-in-class pharmaceuticals to address the needs of patients with kidney disease and vascular disease. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.

History[edit | edit source]

Proteon Therapeutics was founded by Dr. Timothy Noyes and Dr. F. Nicholas Franano in 2001. The company was established with the aim of developing innovative therapies for patients with kidney and vascular diseases. Over the years, Proteon Therapeutics has developed a robust pipeline of drug candidates, with its lead product candidate, vonapanitase, currently in late-stage clinical development.

Products[edit | edit source]

The company's lead product candidate, vonapanitase, is an investigational drug intended for the treatment of chronic kidney disease (CKD) patients undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Vonapanitase is designed to improve the outcomes of surgeries to create arteriovenous fistulas for hemodialysis access.

Clinical Trials[edit | edit source]

Proteon Therapeutics has conducted several clinical trials to evaluate the safety and efficacy of vonapanitase. The company's clinical development program includes two completed Phase 3 clinical trials, PATENCY-1 and PATENCY-2, which evaluated the efficacy of vonapanitase in improving the patency and use of arteriovenous fistulas in patients with chronic kidney disease.

Partnerships[edit | edit source]

Proteon Therapeutics has established strategic partnerships with several pharmaceutical and biotechnology companies to advance its drug development efforts. These partnerships have enabled Proteon to leverage external expertise and resources to accelerate the development of vonapanitase and other drug candidates.

Financials[edit | edit source]

As a publicly traded company, Proteon Therapeutics is subject to financial reporting requirements. The company's financial performance is closely watched by investors and analysts, and its stock is traded on the NASDAQ stock exchange under the ticker symbol "PRTO".

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.